Nationally Notifiable Infectious Diseases and Conditions, United States: Annual Tables

TABLE 4. Reported cases of notifiable diseases and rates per 100,000, by age, excluding U.S. territories - - United States, 2017
Disease <1 yr 1-4 yrs 5-14 yrs 15-24 yrs 25-39 yrs 40-64 yrs ≥65 yrs Age not stated Total
No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. Rate No. No.
Anthrax — — — — — — — — — — — — — — — —
Arboviral diseases
Chikungunya virus disease — — — — 6 0.01 13 0.03 37 0.06 83 0.08 17 0.03 — 156
Eastern equine encephalitis virus disease
Neuroinvasive — — — — — — 1 0.00 1 0.00 3 0.00 — — — 5
Non-neuroinvasive — — — — — — — — — — — — — — — —
Jamestown Canyon virus disease
Neuroinvasive — — — — 3 0.01 4 0.01 6 0.01 26 0.02 19 0.04 — 58
Non-neuroinvasive — — — — — — 1 0.00 3 0.00 7 0.01 6 0.01 — 17
La Crosse virus disease
Neuroinvasive 3 0.08 7 0.04 41 0.10 5 0.01 3 0.00 1 0.00 3 0.01 — 63
Non-neuroinvasive — — — — — — — — — — — — — — — —
Powassan virus disease
Neuroinvasive — — — — 4 0.01 1 0.00 1 0.00 12 0.01 15 0.03 — 33
Non-neuroinvasive — — — — — — — — — — — — 1 0.00 — 1
St. Louis encephalitis virus disease
Neuroinvasive — — — — — — — — 1 0.00 4 0.00 1 0.00 — 6
Non-neuroinvasive — — — — — — — — — — 4 0.00 1 0.00 — 5
West Nile virus disease
Neuroinvasive — — 2 0.01 15 0.04 35 0.08 127 0.19 621 0.60 625 1.23 — 1,425
Non-neuroinvasive — — 4 0.03 7 0.02 41 0.09 145 0.22 325 0.31 150 0.29 — 672
Western equine encephalitis virus disease
Neuroinvasive — — — — — — — — — — — — — — — —
Non-neuroinvasive — — — — — — — — — — — — — — — —
Babesiosis
Total 1 0.03 4 0.03 54 0.17 48 0.14 149 0.29 969 1.20 1,132 2.88 11 2,368
Confirmed 1 0.03 2 0.02 35 0.11 36 0.11 124 0.24 793 0.98 995 2.53 8 1,994
Probable — — 2 0.02 19 0.06 12 0.04 25 0.05 176 0.22 137 0.35 3 374
Botulism
Total 131 3.33 4 0.03 2 0.00 3 0.01 11 0.02 17 0.02 6 0.01 3 177
Foodborne 1 0.03 — — 1 0.00 3 0.01 4 0.01 6 0.01 4 0.01 — 19
Infant * 130 3.30 4 — — — — — — — — — — — 3 137
Other (wound & unspecified) — — — — 1 0.00 — — 7 0.01 11 0.01 2 0.00 — 21
Brucellosis — — 2 0.01 7 0.02 15 0.03 36 0.05 48 0.05 32 0.06 — 140
Campylobacteriosis 1,936 49.15 6,328 39.55 5,270 12.83 7,461 17.25 12,027 18.07 21,445 20.62 12,931 25.43 139 67,537
Chancroid — — — — — — 3 0.01 3 0.00 1 0.00 — — — 7
Chlamydia trachomatis infection 420 10.66 93 0.58 10,893 26.51 1,069,111 2,471.92 540,510 811.89 83,917 80.68 2,178 4.28 1,447 1,708,569
Cholera — — — — — — 1 0.00 3 0.00 4 0.00 2 0.00 — 10
Coccidioidomycosis † 7 0.44 70 1.07 520 3.10 1,200 6.81 2,734 10.15 6,101 14.64 3,725 18.39 7 14,364
Cryptosporidiosis
Total 130 3.30 1,246 7.79 1,306 3.18 1,822 4.21 2,870 4.31 2,680 2.58 1,319 2.59 41 11,414
Confirmed 97 2.46 978 6.11 955 2.32 1,343 3.11 2,081 3.13 1,834 1.76 728 1.43 27 8,043
Probable 33 0.84 268 1.68 351 0.85 479 1.11 789 1.19 846 0.81 591 1.16 14 3,371
Cyclosporiasis — — 9 0.06 17 0.05 90 0.23 278 0.46 546 0.58 222 0.48 32 1,194
Dengue virus infections §
Dengue 1 0.03 2 0.01 33 0.08 57 0.13 139 0.21 169 0.16 36 0.07 — 437
Dengue-like illness — — — — 1 0.00 2 0.00 1 0.00 4 0.00 — — — 8
Severe dengue — — — — — — 1 0.00 4 0.01 4 0.00 — — — 9
Diphtheria — — — — — — — — — — — — — — — —
Ehrlichiosis and Anaplasmosis
Anaplasma phagocytophilum infection — — 24 0.16 147 0.37 156 0.37 479 0.75 2,455 2.44 2,483 5.05 18 5,762
Ehrlichia chaffeensis infection — — 11 0.07 44 0.11 99 0.24 195 0.30 720 0.72 569 1.16 4 1,642
Ehrlichia ewingii infection — — — — — — 1 0.00 2 0.00 25 0.03 17 0.04 — 45
Undetermined ehrlichiosis/anaplasmosis — — 3 0.02 8 0.02 25 0.06 40 0.06 114 0.11 76 0.16 3 269
Giardiasis 113 3.73 1,388 11.26 1,557 4.92 1,792 5.32 3,378 6.49 5,040 6.15 1,883 4.61 42 15,193
Gonorrhea 90 2.28 113 0.71 2,835 6.90 248,470 574.49 237,275 356.40 64,403 61.92 2,063 4.06 359 555,608
Haemophilus influenzae, invasive disease
All ages, all serotypes 363 9.21 262 1.64 116 0.28 137 0.32 354 0.53 1,456 1.40 2,852 5.61 8 5,548
Age <5 years 
Serotype b 17 0.43 16 0.10 — — — — — — — — — — — 33
Non-b serotype 92 2.34 97 0.61 — — — — — — — — — — — 189
Nontypeable 140 3.55 60 0.38 — — — — — — — — — — — 200
Unknown serotype 114 2.89 89 0.56 — — — — — — — — — — — 203
Hansen's disease — — — — 1 0.00 4 0.01 16 0.03 32 0.03 23 0.05 18 94
Hantavirus infection, non-hantavirus pulmonary syndrome — — — — — — 1 0.00 1 0.00 — — — — — 2
Hantavirus pulmonary syndrome — — — — — — 1 0.00 10 0.02 15 0.01 7 0.01 — 33
Hemolytic uremic syndrome post-diarrheal 6 0.16 156 1.00 90 0.22 39 0.09 7 0.01 20 0.02 18 0.04 2 338
Hepatitis **
A, acute 1 0.03 19 0.12 44 0.11 255 0.59 1,358 2.04 1,345 1.29 338 0.66 5 3,365
B, acute — — 2 0.01 — — 99 0.23 1,183 1.79 1,881 1.82 242 0.48 2 3,409
B, perinatal infection †† 22 0.56 8 0.20 — — — — — — — — — — 1 31
C, acute 13 0.35 21 0.14 2 0.01 669 1.63 2,234 3.52 1,149 1.16 105 0.22 32 4,225
Confirmed 11 0.29 18 0.12 1 0.00 514 1.25 1,681 2.65 874 0.88 84 0.17 30 3,213
Probable 2 0.05 3 0.02 1 0.00 155 0.38 553 0.87 275 0.28 21 0.04 2 1,012
Human immunodeficiency virus diagnoses 32 0.81 15 0.09 49 0.12 7,040 16.28 15,561 23.37 10,459 10.06 782 1.54 — 33,938
Influenza-associated pediatric mortality §§ 16 0.41 31 0.19 64 0.16 15 0.12 — — — — — — — 126
Invasive pneumococcal disease ¶¶
All ages 435 14.87 733 6.17 500 1.64 325 1.01 1,491 3.05 8,007 10.30 8,062 20.91 227 19,780
Confirmed 432 14.76 724 6.09 490 1.61 322 1.00 1,481 3.03 7,942 10.22 8,002 20.75 227 19,620
Probable 3 0.10 9 0.08 10 0.03 3 0.01 10 0.02 65 0.08 60 0.16 — 160
Age <5 years  454 14.39 780 6.09 — — — — — — — — — — — 1,234
Confirmed 450 14.27 770 6.01 — — — — — — — — — — — 1,220
Probable 4 0.13 10 0.08 — — — — — — — — — — — 14
Legionellosis 1 0.03 4 0.03 2 0.00 55 0.13 529 0.79 3,453 3.32 3,412 6.71 2 7,458
Leptospirosis — — — — 2 0.01 8 0.02 19 0.04 32 0.04 11 0.03 — 72
Listeriosis 37 0.94 3 0.02 8 0.02 23 0.05 86 0.13 221 0.21 504 0.99 5 887
Lyme disease
Total 24 0.61 1,580 9.92 6,489 15.86 3,801 8.82 5,570 8.40 15,005 14.49 9,396 18.57 878 42,743
Confirmed 21 0.54 1,309 8.22 4,816 11.77 2,500 5.80 3,724 5.62 10,463 10.10 6,034 11.92 646 29,513
Probable 3 0.08 271 1.70 1,673 4.09 1,301 3.02 1,846 2.79 4,542 4.39 3,362 6.64 232 13,230
Malaria 6 0.15 61 0.38 214 0.52 309 0.71 556 0.84 772 0.74 137 0.27 1 2,056
Measles
Total 11 0.28 58 0.36 20 0.05 11 0.03 8 0.01 11 0.01 1 0.00 — 120
Indigenous 7 0.18 55 0.34 18 0.04 7 0.02 5 0.01 6 0.01 1 0.00 — 99
Imported 4 0.10 3 0.02 2 0.00 4 0.01 3 0.00 5 0.00 — — — 21
Meningococcal disease
All serogroups 26 0.66 20 0.13 23 0.06 75 0.17 53 0.08 81 0.08 75 0.15 — 353
Serogroups ACWY 4 0.10 3 0.02 3 0.01 7 0.02 20 0.03 38 0.04 32 0.06 — 107
Serogroup B 12 0.30 6 0.04 7 0.02 37 0.09 6 0.01 11 0.01 11 0.02 — 90
Other serogroups — — 2 0.01 2 0.00 8 0.02 7 0.01 1 0.00 5 0.01 — 25
Unknown serogroup 10 0.25 9 0.06 11 0.03 23 0.05 20 0.03 31 0.03 27 0.05 — 131
Mumps 13 0.33 184 1.15 1,083 2.64 2,471 5.71 1,424 2.14 831 0.80 94 0.18 9 6,109
Novel Influenza A virus infections 1 0.03 8 0.05 9 0.02 1 0.00 — — 1 0.00 — — 46 66
Pertussis 2,237 56.79 2,779 17.37 6,015 14.64 4,204 9.72 1,035 1.55 1,924 1.85 739 1.45 42 18,975
Plague — — — — — — — — — — 3 0.00 2 0.00 — 5
Poliomyelitis, paralytic — — — — — — — — — — — — — — — —
Poliovirus infection, nonparalytic — — — — — — — — — — — — — — — —
Psittacosis — — — — 1 0.00 — — 1 0.00 2 0.00 1 0.00 — 5
Q fever
Total — — — — 3 0.01 4 0.01 25 0.04 103 0.10 58 0.11 — 193
Acute — — — — 3 0.01 3 0.01 21 0.03 83 0.08 43 0.08 — 153
Chronic — — — — — — 1 0.00 4 0.01 20 0.02 15 0.03 — 40
Rabies
Human — — — — — — — — — — 1 0.00 1 0.00 — 2
Rubella — — 1 0.01 — — 2 0.00 1 0.00 2 0.00 1 0.00 — 7
Rubella, congenital syndrome * 5 0.13 — — — — — — — — — — — — — 5
Salmonellosis 5,278 133.98 7,138 44.61 5,418 13.19 5,018 11.60 7,723 11.60 14,219 13.67 9,223 18.13 268 54,285
Severe acute respiratory syndrome-associated coronavirus disease — — — — — — — — — — — — — — — —
Shiga toxin-producing Escherichia coli *** 309 7.84 1,860 11.63 1,383 3.37 1,654 3.82 1,268 1.90 1,209 1.16 921 1.81 68 8,672
Shigellosis 226 5.74 3,036 18.98 2,876 7.00 1,339 3.10 3,048 4.58 3,204 3.08 1,078 2.12 105 14,912
Smallpox — — — — — — — — — — — — — — — —
Spotted fever rickettsiosis
Total 2 0.05 68 0.43 286 0.70 488 1.14 1,209 1.83 2,787 2.70 1,402 2.77 6 6,248
Confirmed — — 7 0.04 7 0.02 6 0.01 37 0.06 84 0.08 35 0.07 — 176
Probable 2 0.05 61 0.38 279 0.68 482 1.12 1,172 1.77 2,703 2.62 1,367 2.71 6 6,072
Streptococcal toxic shock syndrome 4 0.16 4 0.04 17 0.07 11 0.04 58 0.14 156 0.23 122 0.37 — 372
Syphilis
Total, all stages 924 23.46 4 0.03 55 0.13 19,761 45.69 49,521 74.38 29,296 28.17 1,972 3.88 34 101,567
Congenital * 918 23.30 — — — — — — — — — — — — — 918
Primary and secondary 3 0.08 2 0.01 21 0.05 7,001 16.19 15,288 22.96 7,967 7.66 349 0.69 13 30,644
Tetanus — — — — 3 0.01 — — 5 0.01 6 0.01 7 0.01 12 33
Toxic shock syndrome (other than Streptococcal) — — 2 0.02 15 0.05 5 0.02 1 0.00 3 0.00 4 0.01 — 30
Trichinellosis — — — — — — 1 0.00 6 0.01 5 0.01 3 0.01 — 15
Tuberculosis 53 1.35 175 1.09 201 0.49 847 1.96 2,162 3.25 3,354 3.22 2,305 4.53 8 9,105
Tularemia 1 0.03 10 0.06 39 0.09 11 0.03 35 0.05 100 0.10 43 0.08 — 239
Typhoid fever 2 0.05 49 0.31 94 0.23 57 0.13 123 0.18 77 0.07 16 0.03 1 419
Vancomycin-intermediate Staphylococcus aureus — — 2 0.02 1 0.00 6 0.02 15 0.03 39 0.05 46 0.12 — 109
Vancomycin-resistant Staphylococcus aureus — — — — — — — — — — 1 0.00 2 0.00 — 3
Varicella morbidity 724 22.34 1,881 14.31 3,039 9.02 867 2.45 836 1.53 633 0.75 110 0.27 685 8,775
Varicella mortality U U U U U U U U U U U U U U U U
Vibriosis
Total 18 0.46 44 0.28 141 0.35 124 0.29 360 0.55 830 0.81 560 1.12 8 2,085
Confirmed 4 0.10 20 0.13 123 0.30 90 0.21 258 0.39 617 0.60 379 0.76 6 1,497
Probable 14 0.36 24 0.15 18 0.04 34 0.08 102 0.16 213 0.21 181 0.36 2 588
Viral hemorrhagic fevers
Crimean-Congo hemorrhagic fever virus — — — — — — — — — — — — — — — —
Ebola virus — — — — — — — — — — — — — — — —
Guanarito virus — — — — — — — — — — — — — — — —
Junin virus — — — — — — — — — — — — — — — —
Lassa virus — — — — — — — — — — — — — — — —
Lujo virus — — — — — — — — — — — — — — — —
Machupo virus — — — — — — — — — — — — — — — —
Marburg virus — — — — — — — — — — — — — — — —
Sabia virus — — — — — — — — — — — — — — — —
Yellow fever — — — — — — — — — — — — — — — —
Zika virus
Zika virus disease, congenital *,††† 22 0.56 — — — — — — — — — — — — — 22
Zika virus disease, non-congenital — — 4 0.03 15 0.04 84 0.19 172 0.26 183 0.18 39 0.08 — 497
Zika virus infection, congenital *,††† 17 0.43 — — — — — — — — — — — — — 17
Zika virus infection, non-congenital — — — — — — 193 0.45 411 0.62 33 0.03 4 0.01 — 641
  • —: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
  • U: Unavailable — The data are unavailable.
  • * The rate is calculated using population less than 1 year of age.
  • † Reportable in <25 states.
  • § Total number of reported laboratory-positive dengue cases, including all confirmed cases [by anti-dengue virus (DENV) molecular diagnostic methods or seroconversion of anti-DENV IgM] and all probable cases (by a single, positive anti-DENV IgM).
  • ¶ The rate is calculated using population less than 5 years of age.
  • ** Chronic hepatitis B and C data are not included in NNDSS tables but reported case counts are included in the annual Summary of Viral Hepatitis, published online by CDC's Division of Viral Hepatitis, available at https://www.cdc.gov/hepatitis/statistics/2016surveillance/index.htm.
  • †† The rate is calculated using population less than 2 years of age.
  • §§ The rate is calculated using population less than 18 years of age.
  • ¶¶ Includes drug resistant and susceptible cases of Invasive Pneumococcal Disease. This condition was previously named Streptococcus pneumoniae invasive disease and cases were reported to CDC using different event codes to specify whether the cases were drug resistant or in a defined age group, such as <5 years.
  • *** Includes Escherichia coli O157:H7 and Shiga toxin-positive Escherichia coli (including O157, non-O157, and not serogrouped).
  • ††† Data reported to ArboNET using the national surveillance case definition for congenital Zika virus disease or infection (CSTE Position Statement 16-ID-01). Additional data reported to the US Zika Pregnancy Registry for outcomes of pregnancies with laboratory evidence of possible Zika virus infection are available at https://www.cdc.gov/pregnancy/zika/data/pregnancy-outcomes.html. Cases reported to the US Zika Pregnancy Registry might not meet the national surveillance case definition for congenital Zika virus disease or infection.
Notes:
  • These are annual cases of selected infectious national notifiable diseases from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published. Cases are reported by state health departments to CDC weekly. Because source datasets may be updated as additional information is received, statistics in publications based on that source data may differ from what is presented in these tables.
  • The list of nationally notifiable infectious diseases and conditions for 2018 and their national surveillance case definitions are available by navigating to the Surveillance Case Definitions | CDC web page, selecting "2017" for the notifiable condition list year, checking "infectious" conditions, and clicking "Get Notifiable List by Year". This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved in 2016 by CSTE for national surveillance, that were implemented in January 2017, including updated surveillance case definitions for salmonellosis, shigellosis, vibrioisis, perinatal hepatitis B virus infection, invasive pneumococcal disease, Lyme disease, and tularemia reported through August 7, 2018. Publication criteria for the finalized 2017 data are available at https://wonder.cdc.gov/nndss/documents/2017_NNDSS_Publication_Criteria.pdf. See also Guide to Interpreting Provisional and Finalized NNDSS Data.
  • Population estimates for incidence rates are July 1st, 2017 estimates obtained from the National Center for Health Statistics (NCHS) postcensal estimates of the resident population of the United States for April 1, 2010 - July 1, 2017, by year, county, single year of age (range: 0 to 85 years), bridged-race (white, black or African American, American Indian or Alaska Native, Asian, or Pacific Islander), Hispanic ethnicity (not Hispanic or Latino, Hispanic or Latino), and sex (Vintage 2017), prepared under a collaborative arrangement with the U.S. Census Bureau. Population estimates for states released June 27, 2018 are available at https://www.cdc.gov/nchs/nvss/bridged_race/data_documentation.htm. Population estimates for territories are the 2017 mid-year estimates from the U.S. Census Bureau International Data Base, accessed on October 2, 2018 at https://www.census.gov/data-tools/demo/idb/informationGateway.php. The choice of population denominators for incidence is based on the availability of population data at the time of publication preparation.
  • Annual tables for 2016 and later years are available on CDC WONDER.
  • Annual summary reports from 1993-2015 are available as published in the MMWR.
  • NNDSS annual tables since 1952 are available at CDC Stacks (once in CDC Stacks select "Annual Reports" in the "Genre" box to the left).
Suggested Citation: